Clinical trial
A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy Volunteers
NCT02359357 is registered in ClinicalTrials.gov with Flatley Discovery Lab LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy Volunteers
- Lead sponsor
- Flatley Discovery Lab LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- March 31, 2016
- Enrollment
- 130 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.